Medicus Pharma Ltd. (MDCX) is a pre-revenue clinical-stage pharmaceutical company with period end December 31, 2025. Under a liquidation lens, equity recovery is deeply negative. Total assets of $10.1M sit against total liabilities of $10.0M, producing GAAP book equity of approximately $37K on a consolidated basis including noncontrolling interest — and negative $68K attributable to common shareholders. After applying standard liquidation haircuts, recoverable asset value collapses further: cash of $8.7M recovers at par; prepaid expenses of $1.1M and deferred costs of $99K recover at zero or minimal value; operating lease ROU asset of $171K receives a steep haircut. The company holds no inventory, no PP&E of significance, and no separately tagged intangible assets in XBRL — though the filing references in-process R&D clinical programs (SKNJCT-003, SKNJCT-004, and the newly acquired Teverelix via Antev) that receive zero liquidation recovery. Accumulated deficit stands at $64.3M. Net loss for full-year 2025 was $47.3M (attributable to common), a dramatic increase from $7.6M net loss for the nine months ended September 30, 2024. The Antev acquisition (completed August 29, 2025, 98.6% stake) added $2.5M of goodwill/intangibles booked through StockIssuedDuringPeriodValueAcquisitions of $2.5M, which recovers at zero in liquidation. Current liabilities of $9.9M include accounts payable of $3.4M, current debt of $5.2M (debentures issued to YA II PN, Ltd. in September 2025, fair-valued at face), accrued liabilities of $995K, and operating lease current portion of $145K. Long-term obligations include $86K in non-current lease liabilities and $26K in long-term loans. The company has a SEPA facility with Yorkville ($15M capacity, 36-month term) but this is not a committed credit line and does not reduce liquidation liability exposure. Going concern language is explicit in both the current 10-K/A (by reference to the original 10-K) and the prior Q3 10-Q filing. Material weaknesses in internal controls remain unremediated as of September 30, 2025. The filing does not separately tag goodwill or intangible assets from the Antev acquisition in XBRL, though the acquisition is discussed in MD&A and the share issuance value appears in StockIssuedDuringPeriodValueAcquisitions. CEO compensation is routed through RBx Capital LP at $1.2M annually (discussed in MD&A, not separately XBRL-tagged as a liability). D&O insurance premium of $699K annually is a recurring cash obligation not separately tagged. Termination severance obligations exist across employment contracts (12 months for CFO/President, 6 months for CMO and CSO) but are not separately disclosed as contingent liabilities in XBRL.
▼ Community Notes